Announcing the First VitaDAO Research Project:
The Longevity Molecule

1.04 billion prescriptions
4.8 million individuals
50 years of The Danish National Health Service Prescription Database

We’re excited to introduce the opening project to be funded by VitaDAO — the world’s first decentralized intellectual property collective. The research project is led by Morten Scheibye Knudsen and carried out by the Scheibye-Knudsen Lab in Copenhagen.

Who is VitaDAO?

Introducing The Scheibye-Knudsen Lab

The lab discovered that DNA damage leads to changes in certain metabolites and that replenishment of these molecules may alter the rate of aging in model organisms.

These findings, and the ones from other groups, suggest that normal aging and age-associated diseases may be malleable to similar interventions. The hope is to develop interventions that will allow everyone to live healthier, happier, and more productive lives.

Take a short tour of the lab with the founder, Morten:

The Scheibye-Knudsen Lab team comprises a diverse group of distinguished biotech scientists working together in the lab in Copenhagen.

Research Project Overview: The Longevity Molecule

The Scheibye-Knudsen Lab has identified 10+ FDA-approved medications that appear to have a strong effect on lifespan following analysis.

This project will focus on optimizing, repurposing, and re-formulating the three drugs with the strongest and most significant impact on the human lifespan.

Preparing the fly cultures for testing.

Project Significance

Project Timeline

Pre-Clinical Studies 1: Testing in Fruit Flies and Human Cells — 12–24 Months (IN PROGRESS)

We are testing the drugs in human cells with urgency to understand how the molecules affect human cellular aging. Fruit flies are used extensively in biomedical research and specific aging research as they have a short lifespan of about 60 days. We have exclusive access to a deep-learning-based technology ( that can investigate aging in thousands of flies at once.

Fruit Fly (Drosophila melanogaster)

Pre-Clinical Studies 2: Testing in Mouse Models — 12–18 Months

Clinical Trials 1: Human Trials — TBD

Introducing the founder

His focus is on exploring the physiological consequences of DNA damage and what we can do to intervene in genotoxic insults. His goal is to understand, modulate, and treat aging and age-related diseases.

In addition to his academic activities, Morten has founded several companies, including,,, and He is a board member at the Longevity Vision Fund and serves as Chief Editor at Frontiers Media.”

Morten Scheibye-Knudsen, Founder of the Scheibye-Knudsen Lab in Copenhagen (Reference —

If you would like to join the VitaDAO community, get in on the conversation, stay up to date and find ways to contribute — visit our website and community links below!

— Website (
— Twitter (
— Discord Community & Working Groups (

— Telegram Community (
— Would you like to participate? You can fill out our contact form (

VitaDAO is the world’s first decentralized intellectual property collective, funding and commissioning research into human longevity.